BVT Bonus Zert GILD 27.06.2025/ DE000VD5T5D1 /
8/16/2024 5:05:28 PM | Chg.-0.130 | Bid8:05:46 PM | Ask8:05:46 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
67.850EUR | -0.19% | 67.870 Bid Size: 7,800 |
67.940 Ask Size: 7,800 |
Gilead Sciences Inc | - USD | 6/27/2025 | Call |
GlobeNewswire
7/1
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...
GlobeNewswire
7/1
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...
GlobeNewswire
6/28
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
GlobeNewswire
6/26
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
GlobeNewswire
6/26
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
GlobeNewswire
6/18
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...
GlobeNewswire
6/10
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...
GlobeNewswire
5/22
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...
GlobeNewswire
5/14
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
GlobeNewswire
5/9
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...
GlobeNewswire
5/9
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
5/8
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire
5/8
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
4/29
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire
4/19
ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...
GlobeNewswire
4/10
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire
4/2
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
GlobeNewswire
4/1
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...